US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
CARMIEL, Israel, May 25, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on June 7 at 9:00 a.m. ET. The conference is being held at the Grand Hyatt Hotel in New York City.
A live and archived webcast of the presentation will be available at www.protalix.com, on the event calendar page.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others.
Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 [email protected]
